AbbVie annual diluted eps
Diluted EPSBasic EPS
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie EPS History: Annual & Quarterly (ABBV)
AbbVie's diluted EPS was $2.36 for fiscal 2025.
View full AbbVie company overviewAbbVie annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.36 | $2.37 | -$0.03 | −1.26% |
| 2024 | 2024-12-31 | $2.39 | $2.40 | -$0.33 | −12.13% |
| 2023 | 2023-12-31 | $2.72 | $2.73 | -$3.91 | −58.97% |
| 2022 | 2022-12-31 | $6.63 | $6.65 | $0.18 | +2.79% |
| 2021 | 2021-12-31 | $6.45 | $6.48 | $3.73 | +137.13% |
| 2020 | 2020-12-31 | $2.72 | $2.73 | -$2.56 | −48.48% |
| 2019 | 2019-12-31 | $5.28 | $5.30 | $1.62 | +44.26% |
| 2018 | 2018-12-31 | $3.66 | $3.67 | $0.36 | +10.91% |
| 2017 | 2017-12-31 | $3.30 | $3.31 | -$0.33 | −9.09% |
| 2016 | 2016-12-31 | $3.63 | $3.65 | $0.50 | +15.97% |
| 2015 | 2015-12-31 | $3.13 | $3.15 | $2.03 | +184.55% |
| 2014 | 2014-12-31 | $1.10 | $1.11 | -$1.46 | −57.03% |
| 2013 | 2013-12-31 | $2.56 | $2.58 | -$0.79 | −23.58% |
| 2012 | 2012-12-31 | $3.35 | $3.35 | $1.17 | +53.67% |
| 2011 | 2011-12-31 | $2.18 | $2.18 | — | — |
AbbVie quarterly diluted eps
Diluted EPSBasic EPS
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.03 | $2.04 | $1.51 | +290.38% |
| Q1 2026 | 2026-03-31 | $0.39 | $0.39 | -$0.33 | −45.83% |
| Q4 2025 | 2025-12-31 | $1.02 | $1.02 | $1.04 | — |
| Q3 2025 | 2025-09-30 | $0.10 | $0.10 | -$0.78 | −88.64% |
| Q2 2025 | 2025-06-30 | $0.52 | $0.52 | -$0.25 | −32.47% |
| Q1 2025 | 2025-03-31 | $0.72 | $0.72 | -$0.05 | −6.49% |
| Q4 2024 | 2024-12-31 | -$0.02 | -$0.02 | -$0.48 | — |
| Q3 2024 | 2024-09-30 | $0.88 | $0.88 | -$0.12 | −12.00% |
| Q2 2024 | 2024-06-30 | $0.77 | $0.77 | -$0.37 | −32.46% |
| Q1 2024 | 2024-03-31 | $0.77 | $0.77 | $0.64 | +492.31% |
| Q4 2023 | 2023-12-31 | $0.46 | $0.46 | -$0.92 | −66.67% |
| Q3 2023 | 2023-09-30 | $1.00 | $1.00 | -$1.21 | −54.75% |
| Q2 2023 | 2023-06-30 | $1.14 | $1.14 | $0.63 | +123.53% |
| Q1 2023 | 2023-03-31 | $0.13 | $0.13 | -$2.38 | −94.82% |
| Q4 2022 | 2022-12-31 | $1.38 | $1.39 | -$0.88 | −38.94% |
| Q3 2022 | 2022-09-30 | $2.21 | $2.22 | $0.43 | +24.16% |
| Q2 2022 | 2022-06-30 | $0.51 | $0.52 | $0.09 | +21.43% |
| Q1 2022 | 2022-03-31 | $2.51 | $2.52 | $0.52 | +26.13% |
| Q4 2021 | 2021-12-31 | $2.26 | $2.27 | $2.25 | +22500.00% |
| Q3 2021 | 2021-09-30 | $1.78 | $1.78 | $0.49 | +37.98% |
| Q2 2021 | 2021-06-30 | $0.42 | $0.42 | $0.88 | — |
| Q1 2021 | 2021-03-31 | $1.99 | $2.00 | -$0.03 | −1.49% |
| Q4 2020 | 2020-12-31 | $0.01 | $0.01 | -$1.87 | −99.47% |
| Q3 2020 | 2020-09-30 | $1.29 | $1.30 | $0.03 | +2.38% |
| Q2 2020 | 2020-06-30 | -$0.46 | -$0.46 | -$0.95 | — |
| Q1 2020 | 2020-03-31 | $2.02 | $2.02 | $0.37 | +22.42% |
| Q4 2019 | 2019-12-31 | $1.88 | $1.88 | $3.11 | — |
| Q3 2019 | 2019-09-30 | $1.26 | $1.27 | -$0.55 | −30.39% |
| Q2 2019 | 2019-06-30 | $0.49 | $0.49 | -$0.77 | −61.11% |
| Q1 2019 | 2019-03-31 | $1.65 | $1.65 | -$0.09 | −5.17% |
| Q4 2018 | 2018-12-31 | -$1.23 | -$1.23 | -$1.26 | — |
| Q3 2018 | 2018-09-30 | $1.81 | $1.81 | $0.80 | +79.21% |
| Q2 2018 | 2018-06-30 | $1.26 | $1.26 | $0.07 | +5.88% |
| Q1 2018 | 2018-03-31 | $1.74 | $1.74 | $0.68 | +64.15% |
| Q4 2017 | 2017-12-31 | $0.03 | $0.03 | -$0.82 | −96.47% |
| Q3 2017 | 2017-09-30 | $1.01 | $1.02 | $0.04 | +4.12% |
| Q2 2017 | 2017-06-30 | $1.19 | $1.20 | $0.21 | +21.43% |
| Q1 2017 | 2017-03-31 | $1.06 | $1.07 | $0.23 | +27.71% |
| Q4 2016 | 2016-12-31 | $0.85 | $0.86 | -$0.07 | −7.61% |
| Q3 2016 | 2016-09-30 | $0.97 | $0.97 | $0.23 | +31.08% |
| Q2 2016 | 2016-06-30 | $0.98 | $0.99 | $0.15 | +18.07% |
| Q1 2016 | 2016-03-31 | $0.83 | $0.83 | $0.20 | +31.75% |
| Q4 2015 | 2015-12-31 | $0.92 | $0.93 | $1.43 | — |
| Q3 2015 | 2015-09-30 | $0.74 | $0.75 | $0.43 | +138.71% |
| Q2 2015 | 2015-06-30 | $0.83 | $0.84 | $0.15 | +22.06% |
| Q1 2015 | 2015-03-31 | $0.63 | $0.64 | $0.02 | +3.28% |
| Q4 2014 | 2014-12-31 | -$0.51 | -$0.51 | -$1.21 | — |
| Q3 2014 | 2014-09-30 | $0.31 | $0.32 | -$0.29 | −48.33% |
| Q2 2014 | 2014-06-30 | $0.68 | $0.69 | $0.02 | +3.03% |
| Q1 2014 | 2014-03-31 | $0.61 | $0.61 | $0.01 | +1.67% |
| Q4 2013 | 2013-12-31 | $0.70 | $0.70 | -$0.28 | −28.57% |
| Q3 2013 | 2013-09-30 | $0.60 | $0.60 | -$0.41 | −40.59% |
| Q2 2013 | 2013-06-30 | $0.66 | $0.67 | -$0.14 | −17.50% |
| Q1 2013 | 2013-03-31 | $0.60 | $0.61 | $0.04 | +7.14% |
| Q4 2012 | 2012-12-31 | $0.98 | $0.98 | — | — |
| Q3 2012 | 2012-09-30 | $1.01 | $1.01 | — | — |
| Q2 2012 | 2012-06-30 | $0.80 | $0.80 | — | — |
| Q1 2012 | 2012-03-31 | $0.56 | $0.56 | — | — |
AbbVie diluted eps trends
Over the last five fiscal years, AbbVie's diluted eps decreased from $2.72 to $2.36, a change of -$0.36. The latest reported quarter, Q2 2026, shows $2.03.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...